secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surface Oncology, Inc. (—)
CIK:        0001718108
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001193125-23-168488
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 1.02, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surface Oncology to be acquired by Coherus for $40M+ net cash and CVRs
----------------------------------------------------------------------

- Merger consideration per share: Coherus common stock valued using $5.2831 Parent Stock Price and one contingent value right (CVR).
- CVR pays 70% of milestone/royalty payments from GSK/Novartis partnerships over 10 years.
- Terminated HQ lease for $10M payment; loan agreement paid off with $3.25M in fees and expenses.
- Reduced workforce by ~50%; CSO Vito Palombella and CBO Henry Rath departing June 23, 2023.
- Conditions: net cash at closing at least $19.6M, stockholder approval, regulatory clearances; termination fee of $2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1718108/000119312523168488/0001193125-23-168488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1718108/000119312523168488/d497538d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-168488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer